Cambridge Healthtech Institute’s Inaugural

New Small Molecule Drug Targets

RNA, Immunology & Oncology, and the Microbiome

June 2-4, 2020

Small molecule-based therapies have remained a mainstay of drug discovery and development activity, contributing to 75% of new drug approvals in the past five years, with the remaining modalities being comprised mostly of biologic-based therapies. The advantage of small molecules over biologics is their oral bioavailability as well as the fact that only small molecules can enter the cell to modulate the rapidly growing number of intracellular disease targets being identified by scientific research, especially in the areas of immunology, immuno-oncology, cancer, and the microbiome. Moreover, new approaches in biophysical and medicinal chemistry are enabling more effective discovery or design of small molecules that can modulate many of the newer intracellular targets of disease, which often are protein-protein interactions or large molecular complexes that are different from the traditional enzymatic targets of small molecules. The latest new type of intracellular target for which small molecule drug discovery is showing promise and generating excitement about, is RNA-based molecular complexes. Join fellow medicinal chemists and discovery scientists to stay abreast of, share knowledge, and discuss strategies for addressing some of the ‘hottest’ small molecule targets in the biomedical field.


Coverage will include, but is not limited to:


Targeting RNA Complexes with Small Molecules

  • Identifying appropriate target structures
  • Design principles for small molecules
  • Development of chemical probes for unique RNA elements
  • High-throughput techniques to enhance discovery
  • Applications of compounds that target RNA


Immunology & Oncology Small-Molecule Targets

  • Modulators of the innate immune system (e.g. STING)
  • Inhibitors of immune cell metabolism
  • Nuclear receptor targets (e.g. ROR)
  • Remodeling the tumor microenvironment via small molecules
  • Oxygen responsive targets (e.g. HIF1)


Microbiome Small-Molecule Targets

  • Interplay between intestinal bowel disease (IBD) and the microbiome
  • Molecules at the bacteria/host interface


If you would like to submit a proposal to give a presentation at this meeting, please click here.


The deadline for priority consideration is November 22, 2019.


All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.


For more details on the conference, please contact:
Anjani Shah

Senior Conference Director

Cambridge Healthtech Institute

Phone: 781-247-6252



For partnering and sponsorship information, please contact:


Companies A-K

Rod Eymael

Manager, Business Development

Phone: 781-247-6286



Companies L-Z

Joseph Vacca, M.S.

Director, Business Development

Phone: 781-972-5431